二、使用Zeta Life胎牛血清Z7186FBS-500培養(yǎng) 3T3-L1小鼠胚胎成纖維細(xì)胞(前脂肪細(xì)胞)；
三、文章簡(jiǎn)介：乳糖酶抑制劑 通過(guò)下調(diào)脂肪形成 JAK2 / STAT3信號(hào)通路介導(dǎo)的有絲分裂.
四、文章部分內(nèi)容見(jiàn)下：
Cell Culture and Adipocyte Differentiation Induction
3T3-L1 preadipocytes obtained from American Type Culture Collection (ATCC) were maintained in DMEM (SH30022.01, HyClone, CT, USA) containing 10% fetal bovine serum (Z7186FBS-500, ZETA LIFE, Menlo Park, CA, USA). To induce differentiation, 2-day post confluent 3T3-L1 cells (designatedat day 0) were cultured in DMEM containing 10% FBS, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX)(I7018, Sigma-Aldrich, St. Louis, MO, USA), 1 µM dexamethasone (D4902, Sigma-Aldrich, MO, USA),and 10 µg/mL insulin (91077C, Sigma-Aldrich, St. Louis, MO, USA) for two days. Cells were thenmaintained in DMEM containing 10% FBS and 10 µg/mL insulin for the rest of the culture.
產(chǎn)品名稱
貨號(hào)
規(guī)格
Fetal Bovine Serum France Origin
Z7186FBS-500
500ml
Fetal Bovine Serum France Origin
Z7186FBS-100
100ml
Fetal Bovine Serum ,South America Origin
Z7181FBS-500
500ml
Fetal Bovine Serum ,South America Origin
Z7181FBS-100
100ml
Fetal Bovine Serum (South America Origin) Ultra-low Endotoxin
Z7180FBS-500
500ml
Fetal Bovine Serum (South America Origin) Ultra-low Endotoxin
Z7180FBS-100
100ml
Fetal Bovine Serum (Australia Origin）
Z7010FBS-500
500ml
Fetal Bovine Serum (Australia Origin）
Z7010FBS-100
100ml
Fetal Bovine Serum ,South America Origin
Z7185FBS-500
500ml
Fetal Bovine Serum ,South America Origin
Z7185FBS-100
100ml
Zeta Life介紹
美國(guó) Zeta Life 公司成立于 1989 年，是無(wú)血清細(xì)胞培養(yǎng)基 DMEM/F12 主要完成人，有三十多年的胎牛血清、無(wú)血清細(xì)胞培養(yǎng)基、以及干細(xì)胞、免疫細(xì)胞及腫瘤細(xì)胞等多種不同類型哺乳動(dòng)物細(xì)胞的無(wú)血清培養(yǎng)液生產(chǎn)經(jīng)驗(yàn)；也是目前胎牛血清、無(wú)血清培養(yǎng)基較大的 OEM 供應(yīng)商；每批血清均有完整的血源證明文件、獸醫(yī)師檢驗(yàn)證明及品質(zhì)測(cè)試報(bào)告；ZETA LIFE 血清在 100 級(jí)的無(wú)菌間采用全自動(dòng)方式制造生產(chǎn)，具有良好的可再現(xiàn)性及可追溯性。
2018 年美國(guó) Zeta Life 公司與美國(guó)加利福尼亞大學(xué)舊金山校區(qū)聯(lián)合開(kāi)發(fā)活細(xì)胞、活體動(dòng)物體內(nèi)可代謝的 Advanced DNA RNA 轉(zhuǎn)染試劑，此技術(shù)成為蛋白功能、免疫細(xì)胞及干細(xì)胞治療、研發(fā)及生產(chǎn)的主要關(guān)鍵技術(shù)
